Structured evidence table for Omega-3 Dry Eye Randomized Trial, generated from 4 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Omega-3 Dry Eye Randomized Trial | Between-group comparisons revealed significantly higher improvements in the BLT group: Schirmer's test (Schirmer I) improved by MD = 8.7 (95% CI: 7.64-9.76; p = 0.001), TBUT by MD = 2.97 (95% CI: 1.7-4.3; p = 0.007), and DEQS decreased by MD = - 24.1 (95% CI: -37 to - 17.1; p = 0.002). | 2 | Mohamed Elsayed Saad E (2026) | Effect of Bioptron light therapy on dryness of eyes in postmenopausal women: a randomized controlled trial. |
| Omega-3 Dry Eye Randomized Trial | To examine the short-term therapeutic effects of Bioptron light therapy (BLT) on dry eye disease (DED) in postmenopausal women. | 2 | Mohamed Elsayed Saad E (2026) | Effect of Bioptron light therapy on dryness of eyes in postmenopausal women: a randomized controlled trial. |
| Omega-3 Dry Eye Randomized Trial | Sixty postmenopausal women diagnosed with DED, aged 50-62 years with a body mass index ≤ 30 kg/m², were randomly assigned to two equal groups. | 2 | Mohamed Elsayed Saad E (2026) | Effect of Bioptron light therapy on dryness of eyes in postmenopausal women: a randomized controlled trial. |
| Omega-3 Dry Eye Randomized Trial | Purpose To evaluate whether omega-3 fatty acid supplementation is linked to a reduced glaucoma risk in individuals with dry eye disease. | 3 | Pan SY (2026) | Relationship Between Omega-3 Fatty Acids and Glaucoma Risk in Patients With Dry Eye Disease: A Multinational Retrospective Cohort Study. |
| Omega-3 Dry Eye Randomized Trial | The lower risks of ocular hypertension and POAG associated with omega-3 use remained consistent across those aged 60 years or older, females, Whites, and other demographic categories. | 3 | Pan SY (2026) | Relationship Between Omega-3 Fatty Acids and Glaucoma Risk in Patients With Dry Eye Disease: A Multinational Retrospective Cohort Study. |
| Omega-3 Dry Eye Randomized Trial | Conclusions Omega-3 fatty acid supplementations may have the potential to decrease glaucoma risk in individuals with dry eye disease. | 3 | Pan SY (2026) | Relationship Between Omega-3 Fatty Acids and Glaucoma Risk in Patients With Dry Eye Disease: A Multinational Retrospective Cohort Study. |
| Omega-3 Dry Eye Randomized Trial | Methods This retrospective cohort study included adults with dry eye disease from a multinational database between 2013 and 2023. | 3 | Pan SY (2026) | Relationship Between Omega-3 Fatty Acids and Glaucoma Risk in Patients With Dry Eye Disease: A Multinational Retrospective Cohort Study. |
| Omega-3 Dry Eye Randomized Trial | It is also believed that the risk increases with age but there are more and more cases of the disease among 18–50-year-old age groups because of commonly worn contact lenses and worldwide-used electronic devices like smartphones or computers []. | 3 | Pniakowska Zofia (2026) | Dry Eye Disease: From Mechanisms to Management and Future Directions |
| Omega-3 Dry Eye Randomized Trial | This process is accompanied by symptoms reported by patients, and its development is associated with tear film instability, increased osmolarity, inflammatory response, and damage to the barrier of the ocular surface. | 3 | Pniakowska Zofia (2026) | Dry Eye Disease: From Mechanisms to Management and Future Directions |
| Omega-3 Dry Eye Randomized Trial | The aim of the manuscript is to illustrate the pathomechanism and risk factors of DED and to summarize the methods of diagnosis and treatment, including promising solutions that require further development, like smart contact lenses, emulsions, dendrimers or nanomicelles. | 3 | Pniakowska Zofia (2026) | Dry Eye Disease: From Mechanisms to Management and Future Directions |
| Omega-3 Dry Eye Randomized Trial | 1 2 3 4 3 4 5 Dry eye disease (DED) is one of the most common diseases of the ocular surface and is a growing public health problem worldwide. | 3 | Pniakowska Zofia (2026) | Dry Eye Disease: From Mechanisms to Management and Future Directions |
| Omega-3 Dry Eye Randomized Trial | These innovative therapeutic approaches address the partial limitations of conventional treatments through three main molecular mechanisms: improved drug delivery, multitargeted pharmacology, and enhanced biocompatibility. | 4 | Liu J (2026) | Advances in Pharmacotherapy and Physiotherapy for Dry Eye Disease: Molecular Mechanisms and Future Directions-A Narrative Literature Review. |
Source documents